HRS-1893

Phase 2Small molecule

SShandong Suncadia Medicine Co., Ltd.

HRS-1893 is one of 93 small molecule programs targeting Hypertrophic Cardiomyopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypertrophic CardiomyopathyActive, not recruiting

TrialRecruiting

Heart FailureNot yet recruiting

Hypertrophic CardiomyopathyPhase 2

Active, not recruiting

TrialPhase 1

Recruiting

Heart FailurePhase 2

Not yet recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Preclinical

2 2

Medrol

Pfizer

Preclinical

1 3

HRS-1893

SShandong Suncadia Medicine Co., Ltd.

Phase 2

1 4

Zemplar

Adriamycin

Xylocaine

1 7

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 8

Neo-Synephrine

EExela Pharma Sciences, LLC.

Statin

1 10

GLP-1

RRigshospitalet, Denmark

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Obstructive Hypertrophic Cardiomyopathy

NCT07021976

Q2 2027

Phase 2Not yet recruiting

Heart Failure

NCT07269717

Q4 2027

Phase 2Recruiting

Hypertrophic Cardiomyopathy

NCT07021963

Clinical

Trials by Indication[1]

Hypertrophic Cardiomyopathy3 trials

A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy

Completed·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT05879523·76 enrolled

A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2·NCT06516068·42 enrolled

A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy

Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2·NCT07021963·300 enrolled

Trial2 trials

A Trial of HRS-1893 in Healthy Volunteers

Completed·AAtridia Pty Ltd.·Phase 1·NCT07033455·20 enrolled

A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects

Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT07272330·38 enrolled

Function1 trial

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function

Completed·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT06775834·24 enrolled

Heart Failure1 trial

A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction

Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2·NCT07269717·48 enrolled

Obstructive Hypertrophic Cardiomyopathy1 trial

A Multicentre, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HRS-1893 Tablets in the Treatment of Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 3·NCT07021976·228 enrolled

2 more indications

Non-obstructive Hypertrophic Cardiomyopathy1 trial

A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1893 in Non-Obstructive Hypertrophic Cardiomyopathy

Completed·SShandong Suncadia Medicine Co., Ltd.·Phase 2·NCT06816251·84 enrolled

Unspecified1 trial

Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects

Completed·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT06354556·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for HRS-1893. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRS-1893 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRS-1893. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Suncadia Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShandong Suncadia Medicine Co., Ltd.

HRS-1893

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Trials by Indication[1]

Hypertrophic Cardiomyopathy3 trials

Trial2 trials

Function1 trial

Heart Failure1 trial

Obstructive Hypertrophic Cardiomyopathy1 trial

Non-obstructive Hypertrophic Cardiomyopathy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News